Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron vs PEGASYS in Chronic Hepatitis B
NCT01641926Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2012
- Primary completion
- Jan 2016
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
A Phase 3 trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB), sponsored by Merck & Co.. Started Nov 2012; status: terminated.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01641926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01641926.